Top

Published in:

01-08-2013 | Gynecologic Oncology

Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II

Authors: Cheguo Tsai, Juliana S. Leslie, Laura G. Franko-Tobin, Monica C. Prasnal, Tong Yang, L. Vienna Mackey, Joseph A. Fuselier, David H. Coy, Mingqiu Liu, Changyuan Yu, Lichun Sun

Published in: Archives of Gynecology and Obstetrics | Issue 2/2013

Abstract

Purpose

We investigated the effects of the anti-epilepsy drug valproic acid (VPA) alone and in combination in treating cervical cancer.

Methods

VPA was investigated for its effects on cervical cancer Hela cell proliferation and tumor growth via in vitro and in vivo assays.

Results

VPA induce cell growth suppression and cell cycle arrest, with an increase of Notch1 that acts as a tumor suppressor and the change of other tumor-associated genes such as p21, p63 and PCNA. VPA was also found to induce cell morphological change, with an increase of certain cell transformation markers such as snail1, snail2 and N-cadherin. Moreover, VPA could significantly up-regulate somatostatin receptor type II (SSTR2). Our in vivo study further demonstrated that VPA via inducing SSTR2 up-regulation extremely enhanced the anti-tumor ability of the SSTR2-preferential cytotoxic COL-SST conjugate in xenografts.

Conclusions

VPA could not only suppress tumor progression but also provide a novel promising therapeutic choice in combination with a receptor-targeted cytotoxic conjugate via activating the specific receptor.

Maillard I, Pear WS (2003) Notch and cancer: best to avoid the ups and downs. Cancer Cell 3:203–205PubMedCrossRef

Dotto GP (2008) Notch tumor suppressor function. Oncogene 27:5115–5123PubMedCrossRef

Koch U, Radtke F (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64:2746–2762PubMedCrossRef

Talora C, Cialfi S, Segatto O (2005) Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res 305:343–354PubMedCrossRef

Franko-Tobin LG, Mackey LV, Huang W (2011) Notch1-mediated tumor suppression in cervical cancer with the involvement of sst signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist 17:220–232CrossRef

Kostrouchová M, Kostrouch Z, Kostrouchová M (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53:37–49

Platta CS, Greenblatt DY, Kunnimalaiyaan M (2008) Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res 148:31–37PubMedCrossRef

Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206–222PubMedCrossRef

Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA (2007) Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67:1099–1110PubMedCrossRef

10.

Adler JT, Hottinger DG, Kunnimalaiyaan M (2010) Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res 159:640–644PubMedCrossRef

11.

Sami S, Höti N, Xu HM, Shen Z, Huang X (2008) Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 144:357–362PubMedCrossRef

12.

Sun L, Coy DH (2011) Somatostatin receptor-targeted anti-cancer therapy. Cur Drug Deliv 8:2–10CrossRef

13.

Sun L, Luo J, Mackey VL (2007) Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs 18:341–348PubMedCrossRef

14.

Eastham AM, Spencer H, Soncin F (2007) Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 67:11254–11262PubMedCrossRef

15.

Kato Y, Yashiro M, Noda S (2010) Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer 102:898–907PubMedCrossRef

16.

Forino M, Torregrossa R, Ceol M (2006) TGFb1 induces epithelial–mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture. Int J Exp Pathol 87:197–208PubMedCrossRef

17.

Lossi L, Gambino G, Ferrini F (2009) Posttranslational regulation of BCL2 levels in cerebellar granule cells: a mechanism of neuronal survival. Dev Neurobiol 69:855–870PubMedCrossRef

18.

Higashikawa K, Yoneda S, Tobiume K (2007) Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res 67:9207–9213PubMedCrossRef

19.

Gagnon V, Mathieu I, Sexton É (2004) AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94:785–795PubMedCrossRef

20.

Georgeseu MM (2010) PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 1:1170–1177CrossRef

21.

Thiery JP (2002) Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2:442–454PubMedCrossRef

22.

Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389–427PubMedCrossRef

Title: Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II
Authors: Cheguo Tsai
Juliana S. Leslie
Laura G. Franko-Tobin
Monica C. Prasnal
Tong Yang
L. Vienna Mackey
Joseph A. Fuselier
David H. Coy
Mingqiu Liu
Changyuan Yu
Lichun Sun
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 2/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-2762-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Repaired uterine rupture at mid gestation

Cigarette smoke exposure in utero and impact on neurological development: a knockdown of the expression of Hox-genes?

Transvaginal sono-guided aspiration of gestational sac concurrent with a local methotrexate injection for the treatment of unruptured cesarean scar pregnancy

Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India

Non-assessable endometrium in women with post-menopausal bleeding: to investigate or ignore

Olaparib: a promising PARP inhibitor in ovarian cancer therapy